Navigation Links
Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
Date:8/27/2009

TOSU, SAGA, Japan, Aug. 27 /PRNewswire/ -- Hisamitsu Pharmaceutical Co., Inc. (TSE: 4530) today announced the expiration of the subsequent offering period and completion of the tender offer for all outstanding shares of Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) common stock at a price per share of $16.50. The subsequent offering period expired at 12:00 midnight, New York City time, on Wednesday, August 26, 2009 and was not extended.

As of such time, an aggregate of 22,320,889 shares of Noven's common stock, representing approximately 89.18% of Noven's outstanding shares, had been tendered pursuant to the offer. All shares tendered have been accepted for payment and payment for such shares has been or will be made promptly in accordance with the terms of the tender offer.

Hisamitsu also announced that it intends to exercise the option granted by Noven under the merger agreement to purchase from Noven, at a price per share of $16.50, the number of newly issued shares of Noven's common stock that, when added to the number of shares owned by Northstar Merger Sub at the time the option is exercised, will constitute one share more than 90% of Noven's then outstanding shares.

Hisamitsu intends to complete the acquisition of Noven through a short-form merger of Northstar Merger Sub with and into Noven pursuant to the Delaware General Corporation Law, which will not require a vote or meeting of Noven's stockholders, as soon as practicable after the exercise of such option, at which time Noven will become a wholly-owned subsidiary of Hisamitsu U.S., Inc. Following the merger, Noven's common stock will cease to be traded on the NASDAQ Global Stock Market.

About Hisamitsu

Hisamitsu Pharmaceutical Co., Inc. is a leading pharmaceutical company that develops and markets prescription and over-the-counter ("OTC") pharmaceutical products using transdermal delivery systems technology. Its leading product in prescription pharmaceuticals is its Mohrus(R) series (ketoprofen patch for pain), and its leading brand in the OTC business is Salonpas(R). The company was founded in 1847 and is located in Saga, Japan. Additional information is available through its corporate website, http://www.hisamitsu.co.jp.


'/>"/>
SOURCE Hisamitsu Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
2. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
3. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
4. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009
6. Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
7. Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
8. Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals
9. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
10. Raptor Pharmaceuticals Raises $5 Million
11. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, ... announced today that a new solution for Emergency Departments (ED) has been added ... space in Emergency Department examination rooms, and with a simplified pallet of information ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The report forecasts the global optical transceiver ... 2016-2020. The report covers the present scenario and ... To calculate the market size, the report considers the revenue generated ...
(Date:12/9/2016)... Dec. 9, 2016  Harmar Mobility, LLC announced today that Steven ... of the Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... ... Mr. Dawson,s executive career includes ... across a variety of industries. He brings to the company deep ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
Breaking Medicine Technology: